Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...

IN8bio, Inc., a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has reported strong progress in its Phase 1 and Phase 2 clinical programs, showing significant ...

As 2025 comes to a close, the editors at The Scientist asked researchers to reflect on the biggest breakthroughs in cell biology this year. They named advances in everything from embryo models for ...

The global cell cryopreservation market size was valued at US$ 14.9 Bn in 2024 and is projected to reach US$ 104.8 Bn by 2035 ...